Scott Baumgartner

2.6k total citations · 1 hit paper
52 papers, 2.0k citations indexed

About

Scott Baumgartner is a scholar working on Nephrology, Rheumatology and Surgery. According to data from OpenAlex, Scott Baumgartner has authored 52 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Nephrology, 26 papers in Rheumatology and 16 papers in Surgery. Recurrent topics in Scott Baumgartner's work include Gout, Hyperuricemia, Uric Acid (35 papers), Urticaria and Related Conditions (16 papers) and Case Reports on Hematomas (14 papers). Scott Baumgartner is often cited by papers focused on Gout, Hyperuricemia, Uric Acid (35 papers), Urticaria and Related Conditions (16 papers) and Case Reports on Hematomas (14 papers). Scott Baumgartner collaborates with scholars based in United States, New Zealand and Canada. Scott Baumgartner's co-authors include Chris Storgard, Alan Menter, Girish Aras, Elizabeth H. Thompson, Kim Papp, Chris B. Russell, Maple M. Fung, Craig L. Leonardi, Juan Li and James G. Krueger and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Scientific Reports.

In The Last Decade

Scott Baumgartner

51 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

2012 729 citations Kim Papp, Craig L. Leonardi et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott Baumgartner United States	20	938	769	688	684	350	52	2.0k
Meryl Waldman United States	19	839 0.9×	303 0.4×	253 0.4×	101 0.1×	81 0.2×	36	1.5k
Guy Rostoker France	25	689 0.7×	159 0.2×	295 0.4×	250 0.4×	71 0.2×	114	1.9k
Stephen P. McAdoo United Kingdom	27	711 0.8×	643 0.8×	474 0.7×	203 0.3×	20 0.1×	103	2.5k
C.J. Haagsma Netherlands	20	197 0.2×	479 0.6×	2.0k 3.0×	266 0.4×	58 0.2×	38	2.8k
Valderílio Feijó Azevedo Brazil	22	159 0.2×	921 1.2×	860 1.3×	109 0.2×	132 0.4×	116	1.8k
Jhoong S. Cheigh United States	21	587 0.6×	137 0.2×	258 0.4×	358 0.5×	92 0.3×	43	1.5k
Vir Singh Negi India	21	82 0.1×	421 0.5×	458 0.7×	154 0.2×	88 0.3×	108	1.4k
G Feutren France	19	117 0.1×	375 0.5×	144 0.2×	577 0.8×	100 0.3×	50	1.6k
Simone Saibeni Italy	28	57 0.1×	299 0.4×	297 0.4×	850 1.2×	70 0.2×	99	2.3k
Mohammed Yousuf Karim United Kingdom	22	198 0.2×	444 0.6×	707 1.0×	102 0.1×	15 0.0×	59	1.4k

Countries citing papers authored by Scott Baumgartner

Since Specialization

Citations

This map shows the geographic impact of Scott Baumgartner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Baumgartner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Baumgartner more than expected).

Fields of papers citing papers by Scott Baumgartner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Baumgartner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Baumgartner. The network helps show where Scott Baumgartner may publish in the future.

Co-authorship network of co-authors of Scott Baumgartner

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Baumgartner. A scholar is included among the top collaborators of Scott Baumgartner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Baumgartner. Scott Baumgartner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baumgartner, Scott, et al.. (2023). Safety of Catheter Ablation Therapy for Atrial Fibrillation in Cardiac Amyloidosis. Journal of the American Heart Association. 12(14). e029339–e029339. 7 indexed citations

Baumgartner, Scott, et al.. (2023). Delay in prior authorization of biologic therapy: Another possible cause of healthcare disparity in IBD patients. Journal of the National Medical Association. 116(1). 13–15. 3 indexed citations

Khandhar, Sameer, Catalin Toma, William Matthai, et al.. (2022). Mechanical thrombectomy versus catheter directed thrombolysis in patients with pulmonary embolism: A multicenter experience. Catheterization and Cardiovascular Interventions. 101(1). 140–146. 17 indexed citations

Bissonnette, Robert, et al.. (2021). A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatology and Therapy. 11(6). 2179–2193. 10 indexed citations

Dalbeth, Nicola, Graeme Jones, Robert Terkeltaub, et al.. (2019). Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research & Therapy. 21(1). 8–8. 20 indexed citations

Yokose, Chio, Nicola Dalbeth, Jie Wei, et al.. (2019). Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout – A cluster pattern analysis of dual-energy CT. Seminars in Arthritis and Rheumatism. 50(1). 54–58. 9 indexed citations

Iverson, Cory, Sha Liu, Scott Baumgartner, et al.. (2018). Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation. Scientific Reports. 8(1). 1217–1217. 24 indexed citations

Dalbeth, Nicola, Savvas Nicolaou, Scott Baumgartner, et al.. (2017). Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol. Annals of the Rheumatic Diseases. 77(3). 364–370. 47 indexed citations

Perreault, Sylvie, Javier Nuevo, Scott Baumgartner, & Robert Morlock. (2017). Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study. World Journal of Nephrology. 6(3). 132–132. 3 indexed citations

10.

Wood, Robert, et al.. (2016). Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity. The Journal of Rheumatology. 43(10). 1897–1903. 27 indexed citations

11.

Tafesse, Eskinder, P. P. Khanna, Shaum Kabadi, Scott Baumgartner, & Robert Morlock. (2016). THE BURDEN OF TOPHACEOUS AND NON-TOPHACEOUS GOUT IN THE UNITED STATES. Value in Health. 19(3). A231–A231. 1 indexed citations

12.

Bardin, Thomas, Robert T. Keenan, Puja Khanna, et al.. (2016). Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases. 76(5). 811–820. 126 indexed citations

13.

Becker, Michael A., David Fitzpatrick, Hyon K. Choi, et al.. (2015). An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Seminars in Arthritis and Rheumatism. 45(2). 174–183. 90 indexed citations

14.

Doghramji, Paul P., et al.. (2015). Management of gout in the real world: current practice versus guideline recommendations. Postgraduate Medicine. 128(1). 106–114. 11 indexed citations

15.

Pavelká, Karel, Yun Chon, Richard Newmark, et al.. (2015). A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate. The Journal of Rheumatology. 42(6). 912–919. 65 indexed citations

16.

Fleischmann, R., Bradley M. Kerr, Li‐Tain Yeh, et al.. (2014). Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Lara D. Veeken. 53(12). 2167–2174. 81 indexed citations

17.

Gates, Gary J., et al.. (2014). Human Services for Low-Income and At-Risk LGBT Populations: An Assessment of the Knowledge Base and Research Needs. Mathematica Policy Research Reports. 7 indexed citations

18.

Papp, Kim, Craig L. Leonardi, Alan Menter, et al.. (2012). Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis. New England Journal of Medicine. 366(13). 1181–1189. 729 indexed citations breakdown →

19.

Zhang, Jie, Ying Shan, George Reed, et al.. (2011). Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort. Arthritis Care & Research. 63(12). 1672–1679. 42 indexed citations

20.

Varni, James W., Denise Globe, Shravanthi R. Gandra, et al.. (2011). Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. European Journal of Pediatrics. 171(3). 485–492. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact